Neurolief is a neuromodulation company pioneering a new generation of physician-directed therapies for neuropsychiatric and neurological disorders. The company has developed a non-invasive, multi-channel brain neuromodulation platform designed for use in the home and in clinic, enabling targeted stimulation of key neural pathways involved in regulating mood and pain. Neurolief’s lead product, Proliv™Rx, is the first FDA-approved: https://lnkd.in/egj-h-_G prescription neuromodulation therapy for Major Depressive Disorder (MDD) that can be delivered outside of traditional clinical settings for patients who do not adequately respond to antidepressant medications. Neurolief’s technology is also FDA-cleared and CE-marked for the treatment of migraine. Learn more at: www.neurolief.com
Please email MedTech Manager Jeremy Ungar: Jeremy.Ungar@israeltrade.gov.il if you are interested in distributing their product in Australia and New Zealand.
israeltrade.org.au 